Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
5.35
-0.28 (-4.97%)
At close: Mar 5, 2026, 4:00 PM EST
5.44
+0.09 (1.68%)
After-hours: Mar 5, 2026, 6:49 PM EST
Bicycle Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Bicycle Therapeutics stock have an average target of 17.56, with a low estimate of 10 and a high estimate of 44. The average target predicts an increase of 228.22% from the current stock price of 5.35.
Analyst Consensus: Buy
* Price targets were last updated on Nov 24, 2025.
Analyst Ratings
The average analyst rating for Bicycle Therapeutics stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 5 | 5 | 5 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Initiates $10 | Hold | Initiates | $10 | +86.92% | Nov 24, 2025 |
| Citizens | Citizens | Buy Maintains $10 → $12 | Buy | Maintains | $10 → $12 | +124.30% | Oct 31, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $27 → $11 | Buy → Hold | Downgrades | $27 → $11 | +105.61% | Oct 31, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $22 → $10 | Buy | Maintains | $22 → $10 | +86.92% | Aug 12, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $17 → $13 | Hold | Maintains | $17 → $13 | +142.99% | Aug 12, 2025 |
Financial Forecast
Revenue This Year
33.05M
from 35.28M
Decreased by -6.30%
Revenue Next Year
31.16M
from 33.05M
Decreased by -5.74%
EPS This Year
-3.93
from -2.90
EPS Next Year
-3.80
from -3.93
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 41.6M | 63.0M | ||||
| Avg | 33.1M | 31.2M | ||||
| Low | 27.0M | 3.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 17.9% | 90.6% | ||||
| Avg | -6.3% | -5.7% | ||||
| Low | -23.5% | -90.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.84 | -2.56 | ||||
| Avg | -3.93 | -3.80 | ||||
| Low | -4.31 | -4.63 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.